|
Symbol
|
RMBQ5V | KZEHDU | KZFDDU | KZJVDU | RMBAIV | ACMVSQ | ADAATQ | LAGLDU | LALBDU | RMAY9V | ADXETQ | LAUJDU | 1129BC | AEEBTQ | Z0BIGZ | AEACTQ | LAYIDU | AENOTQ | AEHHTQ | LBDPDU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Callable Multi Defender Vonti | Autocallable Multi Barrier Reverse Convertible | Multi Barrier Reverse Convertible | Autocallable Multi Barrier Reverse Convertible | Callable Multi Defender Vonti | Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Multi Barrier Reverse Convertible | Multi Barrier Reverse Convertible | Callable Multi Defender Vonti | Callable Multi Barrier Reverse Convertible | Autocallable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Callable Multi Barrier Reverse Convertible | Autocallable Multi Barrier Reverse Convertible |
|
Sous-jacent
|
Eli Lilly & Co. / Novo Nordisk AS (B) / Roche PS / Ypsomed Hldg. AG | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly / Johnson & Johnson / Pfizer | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) / Ypsomed Hldg. AG | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Lonza Group N / Novo Nordisk AS (B) | Eli Lilly / Johnson & Johnson / Pfizer | Eli Lilly / Johnson & Johnson / Pfizer | Eli Lilly & Co. / Novo Nordisk AS (B) / Ypsomed Hldg. AG | Eli Lilly & Co. / Novartis AG / Novo Nordisk AS (B) / Roche PS | Eli Lilly & Co. / Novartis AG / Novo Nordisk AS (B) / Roche PS | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly / Johnson & Johnson / Pfizer | Bayer AG / Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Intuitive Surgical Inc. / Merck & Co. Inc. | Eli Lilly & Co. / Novo Nordisk AS (B) | Bayer AG / Eli Lilly & Co. / Novo Nordisk AS (B) | Eli Lilly & Co. / Novo Nordisk AS (B) |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
17.11.2026 | 20.11.2026 | 30.11.2026 | 30.12.2026 | 30.12.2026 | 23.11.2026 | 27.11.2026 | 07.12.2026 | 02.07.2027 | 14.01.2027 | 12.02.2027 | 01.03.2027 | 05.03.2027 | 08.12.2026 | 09.03.2027 | 16.03.2027 | 17.03.2027 | 07.04.2027 | 14.01.2027 | 22.04.2027 |
| Demande | 37,500 | 35,350 | - | 33,500 | 46,100 | 66,17 | 63,03 | - | - | 61,00 | 102,41 | 100,60 | 96,63 | 100,80 | - | 99,35 | - | 92,23 | 97,02 | 97,45 |
| Offre | - | 36,350 | - | - | - | - | - | - | - | - | 103,28 | 101,60 | 97,40 | - | - | 100,20 | - | 93,08 | - | 98,45 |